Sphinx Pharma is developing novel combination anti-fungal and anti-cancer drug therapies that significantly reduce toxicity.
Danville, CA, USA
Bodo Knuth Parady
Bodo Parady is the former CEO of Pentum Group, Inc. that received $2.5 million in 5 SBIRs, of a total of nearly $5m, and directing hardware and software development of a leading edge network hardware adapter.
Currently at Children's Hospital, Oakland Research Institute he contributed to various biochemical research projects. He is discoverer of the application of antifungals using massive endocytosis for entry into cancer and fungal cells.
Henrik held a grant for cancer research at CHORI, conducting research on ceramides and sphingosines in breast cancer. He holds patents on application of sphingodienes to cancer.